MediciNova Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

MediciNovaDer Umsatz und der Gewinn des Unternehmens werden voraussichtlich um 122.2% bzw. 10.8% pro Jahr zurückgehen, während der Gewinn pro Aktie voraussichtlich zurückgehen wird.

Wichtige Informationen

-10.8%

Wachstumsrate der Gewinne

-10.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.1%
Wachstumsrate der Einnahmen	-122.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	04 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

Mar 18

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

Oct 12

MediciNova to get US patent for MN-166 to treat brain cancer

Sep 15

MediciNova's MN-166 to be part of study to treat Long COVID

Aug 16

MediciNova begins study of parenteral formulation of MN-166

Jul 22

MediciNova announces extension of BARDA contract for Ibudilast development

Jun 30

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Mar 19

MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

Nov 23

MediciNova: The Pain Of A Positive Outlook

Aug 31

MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study

Jun 21

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

May 15

The MediciNova Riddle: Worth Unravelling

Apr 26

MediciNova inks $20M securities purchase agreement with 3D Investment Partners

Jan 12

MediciNova nabs new U.S. patent for ibudilast in multiple sclerosis

Dec 29

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

Dec 29

MediciNova selected for the Nasdaq Biotechnology Index

Dec 15

MediciNova's MN-166 can reduce retinal thinning in progressive multiple sclerosis

Nov 25

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:MNOV - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-12	N/A	N/A	1
12/31/2025	N/A	-12	N/A	N/A	1
12/31/2024	N/A	-11	N/A	N/A	1
3/31/2024	1	-8	-8	-8	N/A
12/31/2023	1	-9	-7	-7	N/A
9/30/2023	1	-10	-11	-11	N/A
6/30/2023	N/A	-12	-12	-12	N/A
3/31/2023	N/A	-14	-12	-12	N/A
12/31/2022	N/A	-14	-13	-13	N/A
9/30/2022	N/A	-13	-13	-13	N/A
6/30/2022	0	-13	-13	-13	N/A
3/31/2022	0	-13	-9	-9	N/A
12/31/2021	4	-10	-9	-9	N/A
9/30/2021	4	-11	-8	-8	N/A
6/30/2021	4	-11	-9	-9	N/A
3/31/2021	4	-11	-12	-12	N/A
12/31/2020	N/A	-14	-11	-11	N/A
9/30/2020	N/A	-13	-11	-11	N/A
6/30/2020	N/A	-12	-9	-9	N/A
3/31/2020	N/A	-11	-9	-9	N/A
12/31/2019	N/A	-13	-9	-9	N/A
9/30/2019	N/A	-11	-8	-8	N/A
6/30/2019	N/A	-16	-8	-8	N/A
3/31/2019	N/A	-15	-8	-8	N/A
12/31/2018	N/A	-15	-9	-9	N/A
9/30/2018	N/A	-16	-9	-9	N/A
6/30/2018	N/A	-13	-9	-9	N/A
3/31/2018	N/A	-13	-8	-8	N/A
12/31/2017	N/A	-11	N/A	-7	N/A
9/30/2017	N/A	-11	N/A	-7	N/A
6/30/2017	N/A	-10	N/A	-7	N/A
3/31/2017	N/A	-11	N/A	-7	N/A
12/31/2016	N/A	-11	N/A	-7	N/A
9/30/2016	N/A	-12	N/A	-7	N/A
6/30/2016	N/A	-11	N/A	-7	N/A
3/31/2016	N/A	-10	N/A	-6	N/A
12/31/2015	N/A	-9	N/A	-7	N/A
9/30/2015	N/A	-8	N/A	-7	N/A
6/30/2015	N/A	-9	N/A	-7	N/A
3/31/2015	N/A	-9	N/A	-7	N/A
12/31/2014	N/A	-9	N/A	1	N/A
9/30/2014	6	-3	N/A	-2	N/A
6/30/2014	6	-3	N/A	-2	N/A
3/31/2014	6	-4	N/A	-3	N/A
12/31/2013	6	-4	N/A	-11	N/A
9/30/2013	0	-10	N/A	-9	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MNOV wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: MNOV wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: MNOV wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: MNOV wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: MNOV wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von MNOV in 3 Jahren voraussichtlich hoch sein wird

MediciNova Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 69% to US$27.00

Price target decreased by 41% to US$16.00

Price target decreased to US$13.00

Price target decreased to US$13.00

Price target decreased to US$16.00

Consensus revenue estimates increase to US$15.5m

Recent updates

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

MediciNova, Inc. Announces Data from Phase 1B/2A Clinical Trial of Mn-166 (Ibudilast) in Glioblastoma Patients At the American Society of Clinical Oncology (Asco) Annual Meeting 2024

MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)

MediciNova, Inc., Annual General Meeting, Jun 11, 2024

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova, Inc. to Report Q1, 2024 Results on May 10, 2024

MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

Medicinova Announces New Data and Results of Mn-166 (Ibudilast) in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology

Price target increased by 69% to US$27.00

MediciNova, Inc. to Report Fiscal Year 2023 Results on Feb 14, 2024

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

MediciNova, Inc. Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-Induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

MediciNova, Inc. Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

MediciNova, Inc. to Report Q3, 2023 Results on Nov 10, 2023

Price target decreased by 41% to US$16.00

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

MediciNova, Inc. Receives A Notice of Intention to Grant for A New Patent Covering MN-166 (Ibudilast) for the Treatment of Macular Injury in Europe

Less than half of directors are independent

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova, Inc. Announces Presentation of Results from the Phase 2B Trial of Mn-166 (Ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

MediciNova Announces Health Canada Grants Authorization to Commence Multi-Arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID

MediciNova, Inc. Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder

MediciNova, Inc. Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma

MediciNova Receives Notice of Allowance for A New Patent Covering Mn-001 and Mn-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada

MediciNova, Inc. Receives Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil

MediciNova, Inc. Completes Phase I Clinical Trial to Evaluate MN-166 10 MG Intravenous Infusion in Healthy Volunteers

MediciNova, Inc. Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presents at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation

Price target decreased to US$13.00

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

MediciNova, Inc. to Report Q3, 2022 Results on Nov 11, 2022

MediciNova to get US patent for MN-166 to treat brain cancer

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada

MediciNova's MN-166 to be part of study to treat Long COVID

First half 2022 earnings released

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea

MediciNova, Inc Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia

MediciNova, Inc. to Report Q2, 2022 Results on Aug 12, 2022

MediciNova, Inc. Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)

MediciNova begins study of parenteral formulation of MN-166

MediciNova announces extension of BARDA contract for Ibudilast development

MediciNova, Inc. Announces Executive Changes

MediciNova, Inc. Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome

Price target decreased to US$13.00

MediciNova, Inc. to Report Q1, 2022 Results on May 13, 2022

MediciNova, Inc. Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research

MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome

MediciNova, Inc. Announces Plans for A Phase 2 Trial of Mn-001 (Tipelukast) in Nafld with Type 2 Diabetes Mellitus and Hypertriglyceridemia

MediciNova, Inc. Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova, Inc. announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada

MediciNova Receives Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe

MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALS

MediciNova, Inc. Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MND

Medicinova, Inc. Announces New Data Regarding Mn-166 (ibudilast) in Glioblastoma Presented At the 26Th Annual Meeting of the Society for Neuro-Oncology

MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

MediciNova, Inc. Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND

MediciNova: The Pain Of A Positive Outlook

Price target decreased to US$16.00

Chief Medical Officer & Director exercised options to buy US$229k worth of stock.

Consensus revenue estimates increase to US$15.5m

Chief Financial Officer Edward Stepanow has left the company

MediciNova, Inc.(NasdaqGM:MNOV) dropped from Russell 3000 Growth Index

MediciNova, Inc. Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal

MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study

MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury